Abeona Therapeutics Inc
NASDAQ:ABEO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Abeona Therapeutics Inc
NASDAQ:ABEO
|
US |
|
I
|
Intel Corp
MIL:INTC
|
US |
|
Bridgewater Bancshares Inc
NASDAQ:BWB
|
US |
|
P
|
Pitney Bowes Inc
F:PBW
|
US |
|
A
|
Andritz AG
VSE:ANDR
|
AT |
|
D
|
Direct Line Insurance Group PLC
F:D1LN
|
UK |
|
Flex Ltd
NASDAQ:FLEX
|
SG |
|
Larsen & Toubro Ltd
NSE:LT
|
IN |
|
E
|
Entergy Corp
SWB:ETY
|
US |
|
Nuvista Energy Ltd
TSX:NVA
|
CA |
|
Ascelia Pharma AB
STO:ACE
|
SE |
|
A
|
Arribatec Group ASA
F:B7Z
|
NO |
|
Amadeus IT Group SA
MAD:AMS
|
ES |
|
Cantor Equity Partners Inc
NASDAQ:CEP
|
US |
|
China Petroleum & Chemical Corp
SSE:600028
|
CN |
|
F
|
Fluor Corp
DUS:FLU
|
US |
Wall St Price Targets
ABEO Price Targets Summary
Abeona Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for ABEO is 20.4 USD with a low forecast of 13.13 USD and a high forecast of 29.4 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ABEO's stock price target?
Price Target
20.4
USD
According to Wall Street analysts, the average 1-year price target for ABEO is 20.4 USD with a low forecast of 13.13 USD and a high forecast of 29.4 USD.
What is the Revenue forecast for Abeona Therapeutics Inc?
Projected CAGR
71%
Over the last 14 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 8 years is 71%.
What is the Net Income forecast for Abeona Therapeutics Inc?
Projected CAGR
16%
The compound annual growth rate for Net Income over the next 8 years is 16%.
